Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
WikiMesothelioma — Mesothelioma Knowledge Base
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
Editing
Survival Statistics
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== What New Treatments Are Improving Survival in 2025? == Several breakthrough therapies are demonstrating remarkable efficacy and may further improve survival outcomes in the coming years.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/new/ New Mesothelioma Treatments], Mesothelioma Attorney</ref> '''VT3989 (TEAD Inhibitor)''' received FDA Fast Track Designation in October 2025 after demonstrating exceptional results in heavily pretreated patients.<ref>[https://dandell.com/mesothelioma/ Asbestos & Mesothelioma Lawyers], Danziger & De Llano</ref> This first-in-class therapy achieved 86% disease control rate and 32% objective response rate, with median progression-free survival of approximately 10 months—more than double the 15-week benchmark for salvage chemotherapy. A Phase 3 registrational trial is planned for early 2026. '''CAR-T Cell Therapy''' continues showing remarkable durability. Memorial Sloan Kettering's mesothelin-targeted CAR-T program has demonstrated responses lasting beyond 5 years in early patients, with one patient first treated in 2019 remaining disease-controlled as of late 2024.<ref>[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical Trials for Mesothelioma Treatment], Mesothelioma.net</ref> Chinese trials reported 100% objective response rate at higher doses, including durable complete responses. '''BNT327/PM8002 (Bispecific Antibody)''' demonstrated 51.6% confirmed objective response rate and 90.3% disease control rate in Phase 2 trials, representing one of the highest response rates seen in unresectable mesothelioma.<ref>[https://www.mesotheliomalawyercenter.org/entity/mesothelioma/ Mesothelioma], Mesothelioma Lawyer Center</ref> '''ATOMIC-meso (ADI-PEG20)''' achieved its primary endpoint for non-epithelioid mesothelioma, demonstrating a 29% reduction in death risk and quadrupling 3-year survival compared to placebo plus chemotherapy.<ref>[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment], Mesothelioma.net</ref>
Summary:
Please note that all contributions to WikiMesothelioma — Mesothelioma Knowledge Base may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
WikiMesothelioma:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Survival Statistics
(section)
Add topic